European Budget Impact Study Validates Economic Benefits of Blue Light Cystoscopy for Bladder Cancer Diagnosis
核心洞察
A new multi-country budget impact analysis published in the Journal of Medical Economics demonstrates that blue light cystoscopy offers a clinically meaningful and economically rational approach to non-muscle-invasive bladder cancer management across four European healthcare systems.
The study found that in Denmark's differential tariff system, blue light cystoscopy generated a net surplus of €170 per patient, while France and Italy showed modest net costs of €108 and €120 per patient respectively.
Despite varying healthcare payment structures across European countries, the technology consistently reduces the need for early repeat procedures, providing important clinical benefits and cost offsets for hospitals.
Photocure ASA announced the publication of a comprehensive budget impact analysis demonstrating the economic value of blue light cystoscopy (BLC) with hexaminolevulinate across four European healthcare systems. The study, published in the Journal of Medical Economics, provides critical economic evidence for the adoption of enhanced bladder cancer diagnostic technology in diverse reimbursement environments.
Multi-Country Economic Analysis Reveals Variable Cost Impact
The research adapted a previously published budget impact model to explore costs across four different payment environments: Denmark, France, Italy, and Finland. Using consistent clinical assumptions around disease risk profiles, recurrence rates, and photodynamic diagnosis usage, researchers estimated the net budget impact per patient with non-muscle-invasive bladder cancer (NMIBC) over a three-year time horizon from a hospital perspective.
The results revealed significant variation based on healthcare payment structures. In Denmark, which operates a differential tariff system between BLC and white light cystoscopy (WLC), the additional cost of the technology was fully offset by the tariff, generating a net surplus of €170 per patient. France and Italy, both utilizing flat-rate tariffs for BLC and WLC, showed net costs of €108 and €120 per patient respectively. Finland's block contract system resulted in the highest net cost at €206 per patient.
Clinical Benefits Drive Economic Value
Dr. Jonathan Belsey, a health economics expert and study author, emphasized the consistent clinical value across different healthcare systems. "This multi-country budget impact analysis of blue light cystoscopy using hexaminolevulinate demonstrates the consistent clinical and economic value of enhanced diagnostic accuracy in reducing recurrence risk," Belsey stated. "Despite important structural differences across European healthcare systems, the reduction in the requirement for early repeat TURBT is an important clinical benefit."
The study authors concluded that BLC offers a clinically meaningful and economically rational approach to NMIBC management across diverse European healthcare environments. Through flexible, locally tailored budget impact models, stakeholders are better equipped to assess where and how BLC can be integrated into care pathways, supporting both improved patient outcomes and sustainable healthcare resource allocation.
Precision Diagnostics in Evolving Treatment Landscape
Anders Neijber, Photocure's Chief Medical Officer, highlighted the broader implications for bladder cancer care. "The growing number of approved treatment options and advances in technology and AI are accelerating the growth of precision diagnostics in bladder cancer," Neijber explained. "The pharmaceutical advancements, with emerging immune and gene therapies, are transforming care. This requires a more precise diagnosis to better select patients, predict and monitor treatment response and thus ensure the right treatment for the individual patient."
Technology and Disease Context
Hexvix (搜索)/Cysview (hexaminolevulinate HCl) is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy. BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.
Bladder cancer ranks as the 8th most common cancer worldwide and the 5th most common in men, with 1,949,000 prevalent cases, 614,000 new cases, and more than 220,000 deaths in 2022. Approximately 75% of all bladder cancer cases occur in men, and the disease has a high recurrence rate with up to 61% in year one and up to 78% over five years. Bladder cancer has the highest lifetime treatment costs per patient of all cancers.
Non-muscle invasive bladder cancer represents the most common form, accounting for 75% of all bladder cancer cases. These cancers remain in the inner layer of cells lining the bladder and include the subtypes Ta, carcinoma in situ (CIS), and T1 lesions.
Future Research Directions
The study authors noted that diagnostic technologies like BLC often present unique challenges for economic evaluation, requiring linkage between improved detection and downstream clinical and economic outcomes. They recommended that future studies for such technologies should integrate economic endpoints at the trial design stage, enabling better-informed decisions and faster time-to-adoption for patients.